

# OBERWEIS SMALL-CAP OPPORTUNITIES FUND INVESTOR CLASS (OBFOX) INSTITUTIONAL CLASS (OBSIX)

2Q 2017

## AVERAGE ANNUAL TOTAL RETURNS (as of June 30, 2017)

	QTD	YTD	1 Yr	3 Yr	5 Yr	10 Yr	Since Inception 9/15/96	Gross/Net Expense Ratio*
<b>Oberweis Small-Cap Opportunities Fund Investor Class (OBFOX)</b>	<b>0.66%</b>	<b>9.50%</b>	<b>21.36%</b>	<b>5.83%</b>	<b>12.13%</b>	<b>5.11%</b>	<b>6.50%</b>	<b>2.40%/2.00%</b>
<b>Oberweis Small-Cap Opportunities Fund Institutional Class (OBSIX)**</b>	<b>0.75%</b>	<b>9.66%</b>	<b>21.69%</b>	<b>6.11%</b>	<b>12.42%</b>	<b>5.37%</b>	<b>6.77%</b>	<b>1.30%/1.30%</b>
Russell 2000 Growth Index	4.39%	9.97%	24.40%	7.64%	13.98%	7.82%	6.70%	

\* Expense ratio for OBFOX as of 12/31/16. The gross expense ratio includes off set arrangements and expense reimbursement. Expense Ratio is an estimate for the Institutional Class because shares commenced operations on May 1, 2017. Effective May 1, 2017 through April 30, 2018, Oberweis Asset Management, Inc., the Fund's investment advisor, is contractually obligated to reduce its management fees or reimburse OBFOX and OBSIX to the extent that total ordinary operating expenses exceed in any one year 1.55% and 1.30%, respectively, expressed as a percentage of the Fund's average daily net assets. The annual expense ratio for OBFOX will reflect a blend of both the old and new expense reimbursement arrangements in effect for 2017.

\*\*Institutional Class shares OBSIX performance information was calculated using the historical performance of Investor Class shares for periods prior to May 1, 2017.

Performance data shown represents past performance and is no guarantee of future results. Investment return and principal value will fluctuate, so that you may have a gain or loss when shares are sold. Current performance may be higher or lower than quoted. Visit us online at [oberweis.funds.com](http://oberweis.funds.com) for the most recent month-end performance. Before investing, consider the Fund's investment objectives, risks, charges, and expenses. To obtain a copy of the prospectus or summary prospectus containing this and other information, please visit our website at [oberweisfunds.com](http://oberweisfunds.com) or call 800-323-6166. Read it carefully before investing. The Oberweis Funds invest in rapidly growing smaller and medium-sized companies that may offer greater return potential. However, these investments often involve greater risks and volatility. Foreign investments involve greater risks than U.S. investments, including political and economic risks and the risk of currency fluctuations. There is no guarantee that the Funds can achieve their objectives.

The Russell 2000 Growth Index measures the performance of those Russell 2000 companies with higher price-to-book ratios and higher forecasted earnings growth rates. The index is an unmanaged group of stocks, whose performance does not reflect the deduction of fees, expenses or taxes.

The Oberweis Funds are distributed by Oberweis Securities, Inc. Member: FINRA & SIPC.

## The Quarter in Review

The Oberweis Small-Cap Opportunities Fund returned 0.66% during the June quarter versus a 4.39% return for the benchmark Russell 2000 Growth Index, a shortfall of 373 basis points. Year-to-date, the Fund returned 9.50% versus 9.97% for the Russell 2000 Growth Index.

The portfolio faced numerous performance headwinds over the last three months. Although growth continued to outperform value, lower quality stocks led the way within the benchmark as the lowest ROE quintile and the highest P/E ratio quintile – plus the cohort of companies with no P/E's because they lack earnings – performed best during the quarter. The strength among low-quality stocks was particularly evident in the leadership demonstrated by biotechs, which returned 9.3% over the last three months and are responsible for nearly a quarter of the performance of the Russell 2000 Growth so far this year. The best performing sectors within the Russell 2000 Growth Index during the quarter were Utilities, Healthcare (led by the aforementioned strength in biotech), and Real Estate; we are underweight all three sectors and lack meaningful exposure to biotech.

The strength in equities was broad-based globally during the first half of the year as economic growth and corporate earnings have accelerated world-wide, led by emerging markets such as China and India and developed markets including France and Germany. Manufacturing PMI's remained solidly above 50 in Canada, the Eurozone, Australia, Japan, and most emerging markets, signaling continued economic expansion. In the U.S., the PMI also remained above 50, while consumer confidence is at 10-year highs and wages are showing signs of increasing as unemployment flirts with structural cycle lows. Additionally, year-over-year headline inflation has accelerated globally and in the U.S. is around the Fed's 2% target, likely putting to rest the sustained fears of deflation that dogged global economies – particularly those in Europe – since the Global Financial Crisis.

Outside of equities, there were several notable moves in the second quarter that impacted stocks. Oil declined from nearly \$54 per barrel in early April to nearly \$42 in late June, causing Energy to be the worst-performing sector in the index during the quarter. Although the Federal Reserve increased rates for a fourth time in this tightening cycle in June, the yield on the 10-year U.S. Treasury actually fell since March 31, dragging the U.S. dollar – and financial stocks – lower. Lower yields may be a result of a flight to safety as investors seek shelter in response to rising tensions with North Korea and strained relations with Russia.

<sup>1</sup>The Russell 2000 Growth Index returned 4.39% for the June quarter and 9.97% year-to-date while the Russell 2000 Value Index returned 0.67% and 0.54%, respectively.

<sup>2</sup> Biotech stocks contributed 236 basis points of performance to the Russell 2000 Growth Index year-to-date. Source: Jefferies.

## OBERWEIS SMALL-CAP OPPORTUNITIES FUND INVESTOR CLASS (OBSOX) INSTITUTIONAL CLASS (OBSIX)

2Q 2017

### The Quarter In Review (continued)

Meanwhile, U.S. equity valuations remain somewhat elevated but may be supported by improving corporate earnings. Broader market valuations, such as the S&P 500 P/E, are at above-average levels, although in fairness those P/E's are against a backdrop of sustained low interest rates that remain depressed relative to where they would normally be at this point in the cycle. Our universe P/E, which we've tracked since 2003, remains at average levels and is similar to the P/E's we've seen consistently since 2014. We think the market needs continued strength in economic indicators and corporate earnings and eventually corporate tax reform to justify current valuations, particularly those afforded more expensive large-cap stocks.

While mainstream market commentary is generally focused on those pricey large companies, we believe there are still reasons to be intrigued by small-cap growth stocks. First, evidence suggests that small-cap stocks tend to outperform large-caps during periods when the Federal Reserve is well into a tightening regime. According to research by Jefferies small-cap strategist Steven DeSanctis, small-caps traditionally outperform large-caps by over 300 basis points in the year following the fourth rate hike. Following the fifth hike, which we expect in the second half of 2017, that outperformance expands meaningfully to over 1,000 basis points in the subsequent year. Second, Mr. DeSanctis notes that small-cap growth stocks are still cheap relative to small-cap value stocks on several long-term valuation metrics, most notably price-to-cash flow, price-to-sales, and price-to-book value.

While macro factors can influence shorter time periods, we believe that investing in companies growing earnings beyond expectations results in superior investment performance over the long-term. Rather than ruminate about macro-economic indicators or geopolitical events, we focus on investing in individual businesses in which we believe something misunderstood or underestimated is likely to drive earnings growth in excess of consensus expectations. While the multiple paid for such companies may oscillate in the short-run, we believe building portfolios populated with such companies leads to portfolio performance in excess of the benchmark over the long-term.

### Fund Highlights

As of June 30, 2017, the Fund was 94.4% invested in 78 different positions. The Fund had its largest weightings in technology (28.4% average weighting during the quarter versus 20.2% for the Russell 2000 Growth Index), producer durables (17.6% versus 14.0%), and healthcare (15.9% versus 21.9%). In addition to healthcare, the Fund was most underweight materials (5.8% versus 9.7%) and consumer discretionary (13.2% versus 16.0%).

Second quarter performance was positively impacted by stock selection in producer durables (where our holdings returned 5.47% versus a 2.29% return for the benchmark's producer durables holdings), while performance was hindered by our selections in technology (2.22% versus 5.71%) and healthcare (5.41% versus 9.89%, which was impacted by the aforementioned strength in biotech). Performance was also impaired by an overweight to energy (3.4% average weighting during the quarter versus 0.9% for the benchmark), which resulted in a negative allocation effect impact of 63 bps.

### Key Benefits

The Small-Cap Opportunities Fund seeks to capitalize on the exceptional growth potential of smaller companies that are often misunderstood by traditional Wall Street research analysts. The Oberweis Small-Cap Opportunities Fund invests, under normal circumstances, at least 80% of its net assets in the securities of companies (with market capitalizations less than \$5 billion at the time of investment) where our expectations for earnings growth differ from consensus expectations. These companies often boast exciting products and/or services, a strong and sustainable competitive position, and the potential for upward revisions in earnings expectations in the future. Our fundamental research process is specifically designed to efficiently identify such opportunities.

The potential key benefits of the Small-Cap Opportunities Fund are:

- Potential for significant alpha over a full market cycle
- Combines empirically-proven Behavioral Finance principles with the very best of fundamental bottom-up research
- Disciplined and repeatable investment process managed by a passionate and experienced investment team
- Fundamental research process specifically designed to efficiently discover smaller cap companies that are misunderstood by traditional Wall Street research analysts
- Exposure to smaller cap companies offering the potential for earnings growth that differs from consensus expectations
- Diversified portfolio with a focus on risk management

The Oberweis Funds invest in rapidly growing smaller and medium sized companies which may offer greater return potential. However, these investments often involve greater risks and volatility. There is no guarantee that the portfolios can achieve their objectives.

Minimum Investment:

Oberweis Small-Cap Opportunities Fund Investor Class (OBSOX):  
\$1,000 non-IRA, \$500 IRA

Oberweis Small-Cap Opportunities Fund Institutional Class (OBSIX): \$1.0 million

**For more information please contact:**

**John Collins, CIMA®**

**Oberweis Asset Management, Inc.**

**3333 Warrenville Rd., Suite 500, Lisle, IL 60532**

**(800) 323-6166 | (630) 577-2364 | [john.collins@oberweis.net](mailto:john.collins@oberweis.net)**

# OBERWEIS SMALL-CAP OPPORTUNITIES FUND INVESTOR CLASS (OBFOX) INSTITUTIONAL CLASS (OBSIX)

2Q 2017

## FUND CHARACTERISTICS (AS OF JUNE 30, 2017)

Number of Stocks	78
Weighted Market Capitalization (in millions)	\$2,502
Median Market Capitalization (in millions)	\$2,146
P/E Forward 4 Quarters (estimated)	20.8x
Long-Term Future EPS Group Rate (estimated)	12.0%
Long-Term Debt to Total Equity	15.0%
Return on Equity	8.0%
Cash Position	5.6%
Portfolio Turnover (2016)	150%

Source: Thomson Reuters Eikon

## TOP TEN HOLDINGS (as of March 31, 2017)

Company		Line of Business
1 Applied Optoelectronics, Inc.	3.2%	Manufactures advanced optical semiconductor devices
2 Glaukos Corp.	3.0%	Ophthalmic medical technology company
3 Trex Company, Inc.	2.5%	Manufactures non-wood decking products
4 Lumentum Holdings, Inc.	2.3%	Supplies optical and photonic products
5 Coherent, Inc.	2.2%	Manufactures laser-based photonic products
6 Children's Place	2.1%	Retails value-priced apparel and accessories for babies and children up to 12 years old
7 Burlington Stores, Inc.	2.0%	Operates a clothing retail chain
8 Privatebancorp, Inc.	1.9%	Chicago-based bank
9 Tenneco, Inc.	1.9%	Producer of clean air and ride performance products and systems for light vehicle, commercial truck, off-highway and other vehicle applications
10 Cavium, Inc.	1.9%	Provides semiconductor processors that enable intelligent networking, communications, and security applications


Top 10 holdings as a percentage of Total Net Assets. Portfolio Holdings are subject to change at any time. References to specific securities should not be construed as a recommendation to buy or sell and should not be assumed profitable. Source: Thomson Reuters Eikon

**OBERWEIS SMALL-CAP OPPORTUNITIES FUND  
INVESTOR CLASS (OBFOX)  
INSTITUTIONAL CLASS (OBSIX)**

2Q 2017


**SECTOR WEIGHTINGS (as of June 30, 2017)**

Consumer Discretionary	9.8%
Consumer Staples	2.6%
Energy	3.1%
Financial Services	12.1%
Health Care	15.1%
Materials & Processing	5.1%
Producer Durables	20.6%
Technology	26.0%
Utilities	0.0%
Cash	5.6%
<b>Total</b>	<b>100.0%</b>




Sector weightings as a percentage of Total Net Assets. Source: Thomson Reuters Eikon

**GROWTH OF \$10,000 — WITH INCOME INVESTED (September 15, 1996–June 30, 2017)**



The Oberweis Aperture

Our unique, highly disciplined investment approach includes a series of eight criteria to focus our research efforts.



[READ MORE](#)

Oberweis Asset Management, Inc.

Recognized as a leading small-cap stock specialist, Oberweis has been helping institutional investors manage their assets prudently and effectively for many years.

[MEET THE TEAM](#)